Trial Profile
A Multicenter, Randomized, Double-masked Phase 3a Study to Assess Safety and Efficacy of Brolucizumab 6 mg q4 Weeks Compared to Aflibercept 2 mg q4 Weeks in Patients With Neovascular Age-related Macular Degeneration (nAMD) With Persistent Retinal Fluid (MERLIN)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2022
Price :
$35
*
At a glance
- Drugs Brolucizumab (Primary) ; Aflibercept
- Indications Wet age-related macular degeneration
- Focus Registrational; Therapeutic Use
- Acronyms MERLIN
- Sponsors Novartis Pharmaceuticals
- 01 Sep 2022 Results assessing 52-week efficacy and safety of brolucizumab in eyes with neovascular age-related macular degeneration (nAMD) and persistent retinal fluid, published in the Ophthalmology.
- 28 Jul 2022 Status changed from completed to discontinued.
- 12 Oct 2021 Status changed to completed.